Supplemental Table 4. Patient baseline characteristics by presence/absence of diabetes mellitus.

	Patients with diabetes		Patients without diabetes
	Placebo (n = 103)	Evolocumab (n = 94)	Placebo (n = 99)	Evolocumab (n = 108)
CM-C, mg/dL	1.89 ± 2.47	1.69 ± 2.32	1.62 ± 2.76	1.75 ± 2.46
HDL-C, mg/dL	49.56 ± 8.61	52.92 ± 11.21	55.12 ± 12.88	51.43 ± 12.27
LDL-C, mg/dL	90.37 ± 21.26	91.98 ± 21.47	91.90 ± 22.27	96.96 ± 30.14
VLDL-C, mg/dL	34.72 ± 12.17	36.24 ± 12.79	34.86 ± 14.23	36.60 ± 16.72

Abbreviations: CM-C, chylomicron cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol. Data are expressed as mean ± SD. Samples were assessed by high-performance liquid chromatography (HPLC).